Results 41 to 50 of about 8,703 (161)

Multiple genome analysis of Candida glabrata clinical isolates renders new insights into genetic diversity and drug resistance determinants

Microbial Cell, 2022
The emergence of drug resistance significantly hampers the treatment of human infections, including those caused by fungal pathogens such as Candida species.
Pedro Pais, Mónica Galocha, Azusa Takahashi-Nakaguchi, Hiroji Chibana, Miguel C. Teixeira   +4 more
doaj   +1 more source

Mechanisms of echinocandin antifungal drug resistance [PDF]

Annals of the New York Academy of Sciences, 2015
Fungal infections due to Candida and Aspergillus species cause extensive morbidity and mortality, especially among immunosuppressed patients, and antifungal therapy is critical to patient management. Yet only a few drug classes are available to treat invasive fungal diseases, and this problem is compounded by the emergence of antifungal resistance ...
openaire   +2 more sources

Clinical perspectives on echinocandin resistance among Candida species [PDF]

Current Opinion in Infectious Diseases, 2015
We review and offer our clinical perspectives on the emergence of echinocandin-resistant Candida.Candida FKS gene mutations attenuate echinocandin activity, but overall mutation rates among clinical isolates remain low (Candida glabrata, ∼4%; other species,
Ryan K, Shields, M Hong, Nguyen, Cornelius J, Clancy   +2 more
openaire   +2 more sources

Azole-Resistant Aspergillus and Echinocandin-Resistant Candida: What Are the Treatment Options?

Current Fungal Infection Reports, 2020
This review summarizes current treatment options for echinocandin-resistant Candida spp. (ERC) and azole-resistant Aspergillus fumigatus (ARAF), emphasizing recent in vitro/in vivo data, clinical reports, and consensus statements.Advances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant ...
Alison R. Novak, Mary E. Bradley, Tyree H. Kiser, Scott W. Mueller   +3 more
openaire   +3 more sources

Echinocandin-resistant Candida tropicalis Bloodstream Infections [PDF]

Open Forum Infectious Diseases, 2017
BACKGROUND: The aim of this study is to describe the clinical manifestations, molecular mechanisms, and treatment outcomes of patients with echinocandin-resistant Candida tropicalis (C. tropicalis) bloodstream infections (BSI). METHODS: A PubMed search was conducted using the search terms related to C. tropicalis BSI and echinocandin resistance.
Sfeir, Maroun, Jiménez-Ortigosa, Cristina, Schuetz, Audrey, Jenkins, Stephen, Jones, Sian, Soave, Rosemary, Van Besien, Koen, Satlin, Michael, Small, Catherine, Perlin, David, Walsh, Thomas   +10 more
openaire   +1 more source

Invasive Fungal Breakthrough Infections under Targeted Echinocandin Prophylaxis in High-Risk Liver Transplant Recipients

Journal of Fungi, 2023
Invasive fungal infections (IFIs) are frequent and outcome-relevant complications in the early postoperative period after orthotopic liver transplantation (OLT).
Robert Breitkopf, Benedikt Treml, Thomas Senoner, Zoran Bukumirić, Sasa Rajsic   +4 more
doaj   +1 more source

Acquired resistance to echinocandins in Candida albicans: case report and review [PDF]

Journal of Antimicrobial Chemotherapy, 2007
A patient with Candida albicans thrush and oesophagitis was treated with high doses of caspofungin but treatment eventually failed. Four C. albicans isolates were serially recovered before and after caspofungin treatment. A microbiological study was performed to characterize these four isolates.In vitro antifungal susceptibility testing was performed ...
Baixench, Marie-Thérèse, Aoun, Naji, Desnos-Ollivier, Marie, Garcia-Hermoso, Dea, Bretagne, Stéphane, Ramires, Sandrine, Piketty, Christophe, Dannaoui, Eric   +7 more
openaire   +4 more sources

The Mechanisms of Resistance to Echinocandin Class of Antifungal Drugs

Nippon Ishinkin Gakkai Zasshi, 2009
The echinocandin (candin) class of antifungal drugs inhibit beta-1,3-glucan synthase and block synthesis of beta-1,3-glucan , an important polysaccharide in fungal cell walls. Candins are used widely for treatment of systemic infections caused by Candida and Aspergillus because of their high potency and low toxicity to humans.
Niimi, Kyoko, Niimi, Masakazu
openaire   +3 more sources

Differential Regulation of Echinocandin Targets Fks1 and Fks2 in Candida glabrata by the Post-Transcriptional Regulator Ssd1

Journal of Fungi, 2020
Invasive infections caused by the opportunistic pathogen Candida glabrata are treated with echinocandin antifungals that target β-1,3-glucan synthase, an enzyme critical for fungal cell wall biosynthesis. Echinocandin resistance develops upon mutation of
Kelley R. Healey, Padmaja Paderu, Xin Hou, Cristina Jimenez Ortigosa, Nicole Bagley, Biren Patel, Yanan Zhao, David S. Perlin   +7 more
doaj   +1 more source

Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in Candida Glabrata

Advanced Science, EarlyView.
Caspofungin heteroresistance is prevalent in clinical Candida glabrata isolates and depends on calcineurin‐mediated stress adaptation. This transient phenotype serves as a reservoir for resistance evolution, enabling the emergence of stable resistant descendants under prolonged drug pressure.
Yanyu Su, Yi Li, Meng Xiao, Dan Guo, David S. Perlin, Erika Shor, Yingchun Xu, Yingxing Li   +7 more
wiley   +1 more source